News Related to Long-acting Beta Agonist

Related coverage linked through entity extraction aliases.

FDA Approves Breztri Aerosphere as First Triple-Therapy Inhaler for Asthma

Apr 29, 2026

FDA approves AstraZeneca's Breztri Aerosphere as the first single-inhaler triple therapy for asthma in patients aged 12+, based on Phase III KALOS and LOGOS trials showing improved lung function and reduced exacerbations versus dual therapy.

AstraZeneca's Breztri Shows Significant Improvement in Uncontrolled Asthma Patients

Feb 13, 2026

Phase III KALOS and LOGOS trial results published in The Lancet Respiratory Medicine show Breztri Aerosphere improved lung function and reduced severe asthma exacerbations compared to dual-combination therapies in patients with uncontrolled asthma.